RECRUITING

Dominantly Inherited Alzheimer Network (DIAN)

Conditions

Alzheimer's Disease antecedent biomarkers Amyloid Precursor Protein (APP) mutation presenilin I (PS1) mutation presenilin 2 (PS2) mutation Autosomal Dominant Alzheimer's Disease

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.

Official Title

Dominantly Inherited Alzheimer Network (DIAN)

Quick Facts

Study Start:2009-01

Study Completion:2025-07

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT00869817

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Written informed consent obtained from participant and collateral source prior to any study-related procedures. * Aged 18 (inclusive) or older and the child of an affected individual (clinically or by testing) in a pedigree with a known mutation for ADAD. * Cognitively normal to very mild or mild cognitive impairment (CDR score range 0-1.0). Primary enrollment will focus on the recruitment of asymptomatic adult children who are more than 15 years younger than the estimated age of symptom onset. Enrollment of new participants with moderate cognitive impairment is allowed with the prior approval of the DIAN Coordinating Center. * Has two persons who are not their full-blooded siblings who can serve as collateral sources for the study. * Fluent in a language approved by the DIAN Coordinating Center at about the 6th grade level (international equivalent) or above.	* Under age 18 * Medical or psychiatric illness that would interfere in completing initial and follow-up visits * Requires nursing home level care * Has no one who can serve as a study informant

Inclusion Criteria

Exclusion Criteria

* Written informed consent obtained from participant and collateral source prior to any study-related procedures.
* Aged 18 (inclusive) or older and the child of an affected individual (clinically or by testing) in a pedigree with a known mutation for ADAD.
* Cognitively normal to very mild or mild cognitive impairment (CDR score range 0-1.0). Primary enrollment will focus on the recruitment of asymptomatic adult children who are more than 15 years younger than the estimated age of symptom onset. Enrollment of new participants with moderate cognitive impairment is allowed with the prior approval of the DIAN Coordinating Center.
* Has two persons who are not their full-blooded siblings who can serve as collateral sources for the study.
* Fluent in a language approved by the DIAN Coordinating Center at about the 6th grade level (international equivalent) or above.

* Under age 18
* Medical or psychiatric illness that would interfere in completing initial and follow-up visits
* Requires nursing home level care
* Has no one who can serve as a study informant

Contacts and Locations

Study Contact

Alisha Daniels, MD,MHA

CONTACT

(314) 273-9057

DIAN Obs Admin Core

CONTACT

NEURO-DIANCoordinatingCenter@email.wustl.edu

Principal Investigator

Randall J. Bateman, MD

PRINCIPAL_INVESTIGATOR

Washington University School of Medicine

Alisha Daniels, MD,MHA

STUDY_DIRECTOR

(314) 273-9057

Study Locations (Sites)

Mayo Clinic Jacksonville

Jacksonville, Florida, 32224

United States

Indiana University-Indiana Alzheimer Disease Center

Indianapolis, Indiana, 46202

United States

Brigham and Women's Hospital

Boston, Massachusetts, 02115

United States

Washington University in St. Louis School of Medicine

Saint Louis, Missouri, 63108

United States

Columbia University

New York, New York, 10032

United States

University of Pittsburgh

Pittsburgh, Pennsylvania, 15260

United States

Butler Hospital

Providence, Rhode Island, 02906

United States

University of Washington

Seattle, Washington, 98195

United States

Collaborators and Investigators

Sponsor: Washington University School of Medicine

Randall J. Bateman, MD, PRINCIPAL_INVESTIGATOR, Washington University School of Medicine
Alisha Daniels, MD,MHA, STUDY_DIRECTOR, (314) 273-9057

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2009-01

Study Completion Date2025-07

Study Record Updates

Study Start Date2009-01

Study Completion Date2025-07

Terms related to this study

Keywords Provided by Researchers

Alzheimer's disease
antecedent biomarkers
Amyloid Precursor Protein (APP) mutation
presenilin I (PS1) mutation
presenilin 2 (PS2) mutation
Autosomal Dominant Alzheimer's Disease

Additional Relevant MeSH Terms

Alzheimer's Disease